Artiva Biotherapeutics, Inc. (ARTV)
10.22
-0.20
(-1.92%)
USD |
NASDAQ |
Sep 11, 16:00
10.23
+0.01
(+0.10%)
After-Hours: 20:00
Artiva Biotherapeutics Enterprise Value : 159.11M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 159.11M |
| September 10, 2026 | 168.87M |
| September 09, 2026 | 186.92M |
| September 08, 2026 | 191.32M |
| September 04, 2026 | 206.44M |
| September 03, 2026 | 203.27M |
| September 02, 2026 | 212.30M |
| September 01, 2026 | 210.83M |
| August 31, 2026 | 211.81M |
| August 28, 2026 | 201.56M |
| August 27, 2026 | 243.04M |
| August 26, 2026 | 234.74M |
| August 25, 2026 | 234.74M |
| August 24, 2026 | 222.54M |
| August 21, 2026 | 193.75M |
| August 20, 2026 | 204.00M |
| August 19, 2026 | 231.32M |
| August 18, 2026 | 230.35M |
| August 17, 2026 | 233.28M |
| August 14, 2026 | 219.13M |
| August 13, 2026 | 211.81M |
| August 12, 2026 | 223.03M |
| August 11, 2026 | 235.23M |
| August 10, 2026 | 207.90M |
| August 07, 2026 | 210.34M |
| Date | Value |
|---|---|
| August 06, 2026 | 225.47M |
| August 05, 2026 | 225.96M |
| August 04, 2026 | 200.59M |
| August 03, 2026 | 185.46M |
| July 31, 2026 | 153.26M |
| July 30, 2026 | 169.36M |
| July 29, 2026 | 149.35M |
| July 28, 2026 | 174.24M |
| July 27, 2026 | 163.99M |
| July 24, 2026 | 149.84M |
| July 23, 2026 | 154.72M |
| July 22, 2026 | 149.35M |
| July 21, 2026 | 148.38M |
| July 20, 2026 | 106.90M |
| July 17, 2026 | 136.67M |
| July 16, 2026 | 101.54M |
| July 15, 2026 | 144.47M |
| July 14, 2026 | 116.66M |
| July 13, 2026 | 96.17M |
| July 10, 2026 | 130.81M |
| July 09, 2026 | 119.59M |
| July 08, 2026 | 114.71M |
| July 07, 2026 | 123.01M |
| July 06, 2026 | 121.05M |
| July 02, 2026 | 129.35M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Climb Bio, Inc. | 636.66M |
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Oncolytics Biotech, Inc. | 89.25M |
| Sangamo Therapeutics, Inc. | 53.27M |
| Sarepta Therapeutics, Inc. | 2.417B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.00M |
| Total Expenses (Quarterly) | 25.00M |
| EPS Diluted (Quarterly) | -0.6344 |
| Earnings Yield | -32.41% |
| Normalized Earnings Yield | -32.41 |